UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934.

Date of Report: September 29, 2008

(Date of earliest event reported)

Oragenics, Inc

(Exact name of registrant as specified in its charter)


FL	001-38122	59-3410522
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification Number)


13700 Progress Blvd		32615
(Address of principal executive offices)		(Zip Code)

386-418-4018

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 8.01 OTHER EVENTS

Oragenics, Inc. (d/b/a ONI BioPharma Inc.) announced on September 29, 2008 that it had entered into a Collaboration Agreement with a major international diagnostics company regarding ONI’s unique biomarkers for early, middle and late stage colorectal cancer. The Company recently filed a U.S. patent application covering the collection of novel proteins and genes that are specifically expressed in colorectal cancer.

A copy of the September 29, 2008 press release announcing the agreement is attached to this report as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 FINANCIAL INFORMATION AND EXHIBITS

(c) Exhibits.

Number	Description
99.1	Press Release dated September 29, 2008

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 2^nd day of October, 2008.

	ORAGENICS, INC.


	BY:	/s/ David B. Hirsch
		David B. Hirsch Chief Financial Officer